Evidence map›Paper›PMID 42240026›Full record

ArticleCancer biology & therapy2026

Qi Gui, Ying Zhang, Mei Yang, Rongrui Liang, Man Huang, Xiaoshan Yang, Nan Chen, Xiaojun Chen, Mengyao Wu, Huafei Chen and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qi GuiDepartment of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
Ying ZhangAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Mei YangAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Rongrui LiangDepartment of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
Man HuangDepartment of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
Xiaoshan YangAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Nan ChenAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Xiaojun ChenAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Mengyao WuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Huafei ChenAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Lijun MengAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Sheng XiaoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8852-6434
Min TaoDepartment of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpindle cell tumors with

methodsWe report a case of a spindle cell tumor harboring an

resultsMYH10::RET-expressing cells showed significantly higher proliferation, migration, and invasion compared to CCDC6::RET-expressing cells. MYH10::RET exhibited approximately three-fold higher kinase activity. The patient's disease was managed through sequential targeted therapies, including combination therapy with third-generation inhibitors targeting RET and NTRK.

conclusionOur findings suggest that distinct

Indexed as

Oncogene Proteins, FusionProto-Oncogene Proteins c-retSarcomaCell Line, TumorCell ProliferationFemaleHumansMyosin Heavy ChainsMyosin Heavy ChainsOncogene Proteins, FusionProto-Oncogene Proteins c-retRET protein, humankinase activity disparityMYH10::RETNTRK1 fusion resistanceRET fusion heterogeneitysequential targeted therapyundifferentiated spindle cell sarcoma

Identifiers

PMID42240026
PMCPMC13240951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.